drugset / Trial / NCT01441973
Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether elotuzumab will improve response in patients with high risk smoldering myeloma who have more CD56\^dim cells (a marker for the health of the body's immune system)
Timeline
- Start
- 2011-12-28
- Primary completion
- 2014-05-30
- Completion
- 2017-01-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Elotuzumab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | Elotuzumab | Monoclonal antibody | 20 mg/kg | Intravenous |